The Pharmaceutical Benefits Scheme (PBS) has made a groundbreaking announcement, extending the coverage of two immunotherapy drugs to treat multiple cancers. This 'landmark extension' is a significant step forward in cancer treatment, offering hope and financial relief to thousands of Australians. The drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), are now available at a maximum cost of $25, saving patients over $100,000 per treatment course. This move is a world first, as it is the first time a single PBS listing will cover several cancers, removing the 'once-in-a-lifetime' rule for patients with multiple cancer types. Oncologist Dr. Rachel Roberts-Thomson believes this is a turning point, allowing for a more flexible and effective approach to treatment, focusing on the patient's needs rather than specific cancer types. The expansion benefits patients with inoperable, advanced, or metastatic cancers, those who need re-treatment after a relapse, and those requiring longer-term therapy. Rare Cancers Australia's CEO, Christine Cockburn, emphasizes the impact on patients, stating that clinicians can now offer a viable treatment option without the fear of financial burden. Federal Health and Ageing Minister Mark Butler expressed excitement, highlighting the years of hard work and advocacy that led to this announcement. This development is a significant milestone, offering new hope and extended lives to Australians battling advanced cancer.
